A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT ID: NCT05811351

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

305 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-06

Study Completion Date

2026-02-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Geographic Atrophy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm A: JNJ-81201887 Low Dose

Participants will receive a single low dose intravitreal injection of JNJ-81201887 in the study eye on Day 4. In addition, participants will receive a 20-day oral prednisone course starting on Day 1 and a single, long acting periocular triamcinolone (corticosteroid injection) on Day 4 for prophylaxis of intraocular inflammation.

Group Type EXPERIMENTAL

JNJ-81201887

Intervention Type DRUG

JNJ-81201887 will be administered as intravitreal injection.

Prednisone

Intervention Type DRUG

Prednisone will be administered as oral capsule.

Triamcinolone

Intervention Type DRUG

Triamcinolone (corticosteroid injection) periocular injection will be administered as per local practice.

Arm B: JNJ-81201887 High dose

Participants will receive a single high dose intravitreal injection of JNJ-81201887 in the study eye on Day 4. In addition, participants will receive a 20-day oral prednisone course starting on Day 1 and a single, long acting periocular triamcinolone (corticosteroid injection) on Day 4 for prophylaxis of intraocular inflammation.

Group Type EXPERIMENTAL

JNJ-81201887

Intervention Type DRUG

JNJ-81201887 will be administered as intravitreal injection.

Prednisone

Intervention Type DRUG

Prednisone will be administered as oral capsule.

Triamcinolone

Intervention Type DRUG

Triamcinolone (corticosteroid injection) periocular injection will be administered as per local practice.

Arm C: Sham Procedure

Participants will receive sham procedure that matches the single JNJ21801887 injection on Day 4, a sham procedure that matches the long acting periocular triamcinolone (corticosteroid injection) on Day 4 and a 20-day placebo matching oral prednisone starting on Day 1.

Group Type SHAM_COMPARATOR

Placebo

Intervention Type OTHER

Prednisone matching placebo will be administered as oral capsule.

Sham Procedure

Intervention Type OTHER

Sham injections matching to single JNJ-81201887 injection and matching to corticosteroid (triamcinolone) periocular injection will be administered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JNJ-81201887

JNJ-81201887 will be administered as intravitreal injection.

Intervention Type DRUG

Prednisone

Prednisone will be administered as oral capsule.

Intervention Type DRUG

Placebo

Prednisone matching placebo will be administered as oral capsule.

Intervention Type OTHER

Triamcinolone

Triamcinolone (corticosteroid injection) periocular injection will be administered as per local practice.

Intervention Type DRUG

Sham Procedure

Sham injections matching to single JNJ-81201887 injection and matching to corticosteroid (triamcinolone) periocular injection will be administered.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AAVCAGsCD59

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have non-subfoveal (defined as not involving the center point of the fovea) geographic atrophy (GA) secondary to age-related macular degeneration (AMD) with an area that can be measured and measures 2.5 millimeter square (mm\^2) to 17.5 mm\^2 (1- and 7- disc areas respectively), determined by the central reading center (CRC) from screening images of fundus autofluorescence (FAF) and spectral domain optical coherence tomography (SD-OCT)
* If GA is multifocal, at least one focal lesion must be greater than or equal to (\>=) 1.25 mm\^2 (0.5- disc area), as assessed by the CRC
* GA can be photographed in its entirety by FAF, using a 30- degree image centered on the fovea, as assessed by the CRC
* Fellow eye must be present with a best corrected distance visual acuity (BCVA) of counting fingers or better
* Man or woman (according to their reproductive organs and functions assigned by chromosomal complement)

Exclusion Criteria

* History of transpupillary thermotherapy, photodynamic therapy or external-beam radiation therapy in the region of study eye
* Any prior thermal laser in the macular region, regardless of indication
* History of retinal detachment (with or without repair)
* Active, infectious conjunctivitis, keratitis, scleritis, or endophthalmitis
* Any sign of diabetic retinopathy or central serous chorioretinopathy
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Janssen Research & Development, LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Janssen Research & Development, LLC Clinical Trial

Role: STUDY_DIRECTOR

Janssen Research & Development, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Retinal Research Institute

Phoenix, Arizona, United States

Site Status

Retina Associates Southwest PC

Tucson, Arizona, United States

Site Status

Retina Consultants of Orange County

Fullerton, California, United States

Site Status

Retina Associates Of Southern California

Huntington Beach, California, United States

Site Status

Shiley Eye Institute Jacobs Retina Center

La Jolla, California, United States

Site Status

Jules Stein Eye Institute UCLA

Los Angeles, California, United States

Site Status

The Retina Partners

Los Angeles, California, United States

Site Status

California Retina Consultants

Oxnard, California, United States

Site Status

Stanford Health Care

Palo Alto, California, United States

Site Status

California Eye Medical Specialists

Pasadena, California, United States

Site Status

Retina Consultants San Diego

Poway, California, United States

Site Status

Retina Consultants of Southern California

Redlands, California, United States

Site Status

Bay Area Retina Associates

Walnut Creek, California, United States

Site Status

Colorado Retina - Lakewood Clinic

Lakewood, Colorado, United States

Site Status

Retina Group of Florida

Fort Lauderdale, Florida, United States

Site Status

National Opthalmic Research Institute

Fort Myers, Florida, United States

Site Status

VitreoRetinal Associates, PA

Gainesville, Florida, United States

Site Status

MedEye Associates

Miami, Florida, United States

Site Status

Retina Specialty Institute

Pensacola, Florida, United States

Site Status

Fort Lauderdale Eye Institute

Plantation, Florida, United States

Site Status

Retina Vitreous Associates of Florida

St. Petersburg, Florida, United States

Site Status

East Florida Eye Institute

Stuart, Florida, United States

Site Status

Georgia Retina

Marietta, Georgia, United States

Site Status

Marietta Eye Clinic

Marietta, Georgia, United States

Site Status

University Of Illinois

Chicago, Illinois, United States

Site Status

Retina Associates

Elmhurst, Illinois, United States

Site Status

University Retina

Lemont, Illinois, United States

Site Status

Midwest Eye Institute

Carmel, Indiana, United States

Site Status

Maine Eye Center

Portland, Maine, United States

Site Status

Retina Specialists

Baltimore, Maryland, United States

Site Status

The Retina Care Center

Baltimore, Maryland, United States

Site Status

The Retina Group of Washington

Chevy Chase, Maryland, United States

Site Status

Cumberland Valley Retina Consultants

Hagerstown, Maryland, United States

Site Status

Ophthalmic Consultants of Boston

Boston, Massachusetts, United States

Site Status

Vitreo Retinal Associates-Worcester

Worcester, Massachusetts, United States

Site Status

Foundation for Vision Research

Grand Rapids, Michigan, United States

Site Status

Associated Retinal Consultants P.C.

Royal Oak, Michigan, United States

Site Status

Retina Consultants of Minnesota

Saint Louis Park, Minnesota, United States

Site Status

The Retina Institute

St Louis, Missouri, United States

Site Status

Sierra Eye Associates

Reno, Nevada, United States

Site Status

Wills Eye/Mid Atlantic Retina

Cherry Hill, New Jersey, United States

Site Status

Long Island Vitreo Retinal Consultants

Great Neck, New York, United States

Site Status

Retina-Vitreous Surgeons of Central New York

Liverpool, New York, United States

Site Status

Vitreous Retina Macula Consultants of New York

New York, New York, United States

Site Status

Retina Consultants PLLC

Slingerlands, New York, United States

Site Status

Opthalmic Consultants of the Capital Region

Troy, New York, United States

Site Status

Asheville Eye Associates - Western Carolina Retinal Associates

Asheville, North Carolina, United States

Site Status

Duke University

Durham, North Carolina, United States

Site Status

Graystone Eye

Hickory, North Carolina, United States

Site Status

NC Retina Associates

Wake Forest, North Carolina, United States

Site Status

Cincinnati Eye Institute

Cincinnati, Ohio, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

Verum Research LLC

Eugene, Oregon, United States

Site Status

Casey Eye Institute

Portland, Oregon, United States

Site Status

Cascade Medical Research Institute, LLC

Springfield, Oregon, United States

Site Status

Erie Retina Research

Erie, Pennsylvania, United States

Site Status

Charleston Neuroscience Institute, LLC

Beaufort, South Carolina, United States

Site Status

Charles Retina Institute

Germantown, Tennessee, United States

Site Status

Retina Research Institute of Texas

Abilene, Texas, United States

Site Status

Panhandle Eye Group LLP-Southwest Retina Specialists

Amarillo, Texas, United States

Site Status

Austin Clinical Research

Austin, Texas, United States

Site Status

Retina and Vitreous of Texas, PLLC

Bellaire, Texas, United States

Site Status

Retina Consultants of Texas

Bellaire, Texas, United States

Site Status

Retina Foundation of the Southwest

Dallas, Texas, United States

Site Status

Texas Retina Associates

Dallas, Texas, United States

Site Status

UT Southwestern

Dallas, Texas, United States

Site Status

Texas Retina Associates

Fort Worth, Texas, United States

Site Status

Houston Eye Associates

Houston, Texas, United States

Site Status

San Antonio Eye Center

San Antonio, Texas, United States

Site Status

Retina Associates Of South Texas P A

San Antonio, Texas, United States

Site Status

Retina Consultants of Texas

San Antonio, Texas, United States

Site Status

Retina Consultants of Texas

The Woodlands, Texas, United States

Site Status

Strategic Clinical Research Group

Willow Park, Texas, United States

Site Status

Retina Associates of Utah P C

Salt Lake City, Utah, United States

Site Status

Rocky Mountain Retina Consultants

Salt Lake City, Utah, United States

Site Status

University of Utah

Salt Lake City, Utah, United States

Site Status

Piedmont Eye Center

Lynchburg, Virginia, United States

Site Status

Wagner Kapoor Research institute

Norfolk, Virginia, United States

Site Status

Spokane Eye Clinical Research

Spokane, Washington, United States

Site Status

Adelaide Eye and Retina Centre

Adelaide, , Australia

Site Status

Centre for Eye Research Australia

East Melbourne, , Australia

Site Status

Strathfield Retina Clinic

Strathfield, , Australia

Site Status

Sydney Retina Clinic and Day Surgery

Sydney, , Australia

Site Status

Sydney West Retina

Westmead, , Australia

Site Status

Ziekenhuis Oost-Limburg

Genk, , Belgium

Site Status

UZ Gent

Ghent, , Belgium

Site Status

UZ Leuven Gasthuisberg

Leuven, , Belgium

Site Status

Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman

Liège, , Belgium

Site Status

Calgary Retina Consultants

Calgary, Alberta, Canada

Site Status

Alberta Retina Consultants

Edmonton, Alberta, Canada

Site Status

The Ottawa Hospital Research Institute

Ottawa, Ontario, Canada

Site Status

The Retina Centre of Ottawa

Ottawa, Ontario, Canada

Site Status

Institut De L'oeil Des Laurentides

Boisbriand, Quebec, Canada

Site Status

OFTEX Ltd. - EYE CENTER

Pardubice, , Czechia

Site Status

Fakultni nemocnice Kralovske Vinohrady

Prague, , Czechia

Site Status

AXON Clinical s.r.o.

Prague, , Czechia

Site Status

Aalborg University Hospital

Aalborg, , Denmark

Site Status

University Hospital Of Copenhagen, Glostrup Hospital

Glostrup Municipality, , Denmark

Site Status

Zealand University Hospital

Roskilde, , Denmark

Site Status

Charite Universitaetsmedizin Berlin

Berlin, , Germany

Site Status

Universitaets-Augenklinik Bonn

Bonn, , Germany

Site Status

Universitatsklinikum Gießen - Klinik und Poliklinik fur Augenheilkunde

Giessen, , Germany

Site Status

Klinikum Gottingen der Georg August Universitat

Göttingen, , Germany

Site Status

Medizinische Hochschule Hannover

Hanover, , Germany

Site Status

Universitatsklinikum Schleswig Holstein Kiel

Kiel, , Germany

Site Status

Universitaetsklinikum Leipzig

Leipzig, , Germany

Site Status

Klinikum Ludwigshafen

Ludwigshafen am Rhein, , Germany

Site Status

Augenzentrum am St Franziskus Hospital Munster

Münster, , Germany

Site Status

Universitaetsklinikum Muenster

Münster, , Germany

Site Status

Universitaetsklinikum Tuebingen

Tübingen, , Germany

Site Status

Eszak Pesti Centrumkorhaz Honvedkorhaz

Budapest, , Hungary

Site Status

Ganglion Orvosi Központ

Pécs, , Hungary

Site Status

Zala Megyei Szent Rafael Korhaz

Zalaegerszeg, , Hungary

Site Status

Arcispedale S. Anna Ferrara

Ferrara, , Italy

Site Status

Fondazione IRCCS Ca Granda Ospedale Policlinico Di Milano

Milan, , Italy

Site Status

Ospedale San Raffaele

Milan, , Italy

Site Status

Sacco Hospital

Milan, , Italy

Site Status

Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli

Napoli, , Italy

Site Status

Policlinico Universitario Agostino Gemelli

Roma, , Italy

Site Status

Amsterdam University Medical Centers Location Academic Medical Center

Amsterdam, , Netherlands

Site Status

Radboudumc

Nijmegen, , Netherlands

Site Status

Het Oogziekenhuis Rotterdam

Rotterdam, , Netherlands

Site Status

Oculomedica

Bydgoszcz, , Poland

Site Status

Oftalmika

Bydgoszcz, , Poland

Site Status

Uno Med

Tarnów, , Poland

Site Status

Warszawski Szpital Okulistyczny

Warsaw, , Poland

Site Status

Uls Coimbra - Hosp. Univ. Coimbra

Coimbra, , Portugal

Site Status

Espaco Medico de Coimbra

Coimbra, , Portugal

Site Status

Uls Sao Joao - Hosp. Sao Joao

Porto, , Portugal

Site Status

Centro de Oftalmologia Barraquer

Barcelona, , Spain

Site Status

Centro Medico Teknon S.L.

Barcelona, , Spain

Site Status

Inst. Cat. de Retina

Barcelona, , Spain

Site Status

Hosp. Dos de Maig

Barcelona, , Spain

Site Status

Inst. de Microcirugia Ocular

Barcelona, , Spain

Site Status

Clinica Oftalvist Valencia

Burjassot, , Spain

Site Status

Hosp. La Arruzafa

Córdoba, , Spain

Site Status

Hosp. Univ. Donostia

Donostia / San Sebastian, , Spain

Site Status

Hosp Univ Fund Jimenez Diaz

Madrid, , Spain

Site Status

Hosp. Univ. 12 de Octubre

Madrid, , Spain

Site Status

Clinica Baviera Madrid Castellana

Madrid, , Spain

Site Status

Hosp. Univ. Pta. de Hierro Majadahonda

Majadahonda, , Spain

Site Status

Clinica Univ. de Navarra

Pamplona, , Spain

Site Status

Idc Salud Hosp. Gral. de Catalunya

Sant Cugat del Vallès, , Spain

Site Status

Hosp. Prov. Do Conxo

Santiago de Compostela, , Spain

Site Status

Hosp. Virgen Del Rocio

Seville, , Spain

Site Status

Hosp. Clinico Univ. Lozano Blesa

Zaragoza, , Spain

Site Status

Hosp. Univ. Miguel Servet

Zaragoza, , Spain

Site Status

S:t Eriks Ogonsjukhus

Stockholm, , Sweden

Site Status

Inselspital Universitatsspital Bern

Bern, , Switzerland

Site Status

Hacettepe University Hospital

Ankara, , Turkey (Türkiye)

Site Status

Baskent University Ankara Hospital

Ankara, , Turkey (Türkiye)

Site Status

Ankara Bilkent Sehir Hastanesi

Ankara, , Turkey (Türkiye)

Site Status

Dokuz Eylul University Hospital

Izmir, , Turkey (Türkiye)

Site Status

Konya Selcuk University Medical Faculty

Konya, , Turkey (Türkiye)

Site Status

Bristol Eye Hospital

Bristol, , United Kingdom

Site Status

Moorfields Eye Hospital

London, , United Kingdom

Site Status

Central Middlesex Hospital

London, , United Kingdom

Site Status

The Retina Clinic London

London, , United Kingdom

Site Status

Manchester Royal Eye Hospital

Manchester, , United Kingdom

Site Status

Royal Victoria Infirmary

Newcastle upon Tyne, , United Kingdom

Site Status

Oxford Eye Hospital

Oxford, , United Kingdom

Site Status

Southampton University Hospital

Southampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Argentina United States Australia Belgium Canada Czechia Denmark Germany Hungary Italy Netherlands Poland Portugal Spain Sweden Switzerland Turkey (Türkiye) United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

81201887MDG2001

Identifier Type: OTHER

Identifier Source: secondary_id

2022-500746-16-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

CR109236

Identifier Type: -

Identifier Source: org_study_id